Fourcade 2014 Biochimie

From Bioblast
Revision as of 11:24, 9 March 2015 by Bader Helga (talk | contribs) (moved Fourcade 2013 Biochimie to Fourcade 2014 Biochimie)
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Publications in the MiPMap
Fourcade S, LΓ³pez-Erauskin J, Ruiz M, Ferrer I, Pujol A (2014) Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. Biochimie 98:143-9.

Β» PMID: 24076127

Fourcade S, Lopez-Erauskin J, Ruiz M, Ferrer I, Pujol A (2014) Biochimie

Abstract: X-linked adrenoleukodystrophy (X-ALD) is the most frequent inherited monogenic demyelinating disease (minimal incidence 1:17,000). It is often lethal and currently lacks a satisfactory therapy. The disease is caused by loss of function of the ABCD1 gene, a peroxisomal ATP-binding cassette transporter, resulting in the accumulation of VLCFA (very long-chain fatty acids) in organs and plasma. Understanding of the aetiopathogenesis is a prerequisite for the development of novel therapeutic strategies. Functional genomics analysis of an ABCD1 null mouse, a mouse model for adrenomyeloneuropathy, has revealed presymptomatic alterations in several metabolic pathways converging on redox and bioenergetic homeostasis, with failure of mitochondrial OXPHOS disruption and mitochondrial depletion. These defects could be major contributors to the neurodegenerative cascade, as has been reported in several neurodegenerative disorders. Drugs targeting the redox imbalance/mitochondria dysfunction interplay have shown efficacy at halting axonal degeneration and associated disability in the mouse, and thus offer therapeutic hope. β€’ Keywords: Cyclophilin D, Mitochondria dysfunction, Oxidative damage, Proteasome, Very long-chain fatty acids, X-linked adrenoleukodystrophy

Labels: MiParea: mt-Medicine, Patients  Pathology: Inherited 

Organism: Human 


Cookies help us deliver our services. By using our services, you agree to our use of cookies.